672 related articles for article (PubMed ID: 18018383)
1. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
2. Clinical review: the use of vaptans in clinical endocrinology.
Peri A
J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
[TBL] [Abstract][Full Text] [Related]
3. [Vasopressin receptor antagonists: the vaptans].
Villabona C
Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
5. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
Verbalis JG
Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
[TBL] [Abstract][Full Text] [Related]
6. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
Urso C; Brucculeri S; Caimi G
J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin excess and hyponatremia.
Pham PC; Pham PM; Pham PT
Am J Kidney Dis; 2006 May; 47(5):727-37. PubMed ID: 16632011
[TBL] [Abstract][Full Text] [Related]
8. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
[TBL] [Abstract][Full Text] [Related]
9. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
[TBL] [Abstract][Full Text] [Related]
10. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
13. The use of vasopressin receptor antagonists in hyponatremia.
Khanna A; Menon MC
Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan for hyponatremia.
Weise WJ; Rimmer JM; Hood VL
N Engl J Med; 2007 Mar; 356(9):961; author reply 962-3. PubMed ID: 17329708
[No Abstract] [Full Text] [Related]
15. [Treatment of hyponatremia: role of vaptans].
Hensen J
Internist (Berl); 2010 Dec; 51(12):1499-509. PubMed ID: 21104220
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for hyponatremia in heart failure.
Goldsmith SR
Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
Gargani L; Schmidt PH; Gheorghiade M
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
[TBL] [Abstract][Full Text] [Related]
18. Cerebral correlates of hyponatremia.
Nathan BR
Neurocrit Care; 2007; 6(1):72-8. PubMed ID: 17356196
[TBL] [Abstract][Full Text] [Related]
19. [Current options of treatment of hyponatremia].
Tesař V
Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
[TBL] [Abstract][Full Text] [Related]
20. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
Gross PA; Wagner A; Decaux G
Kidney Int; 2011 Sep; 80(6):594-600. PubMed ID: 21451459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
